Wells Fargo Maintains Overweight on Sangamo Therapeutics, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Yanan Zhu has maintained an Overweight rating on Sangamo Therapeutics (NASDAQ:SGMO) but lowered the price target from $5 to $4.

August 10, 2023 | 2:08 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Wells Fargo has maintained an Overweight rating on Sangamo Therapeutics but lowered the price target from $5 to $4.
The lowering of the price target by Wells Fargo from $5 to $4 indicates a potential decrease in the stock's value. However, the maintained Overweight rating suggests that the stock is still expected to outperform the market, which could mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100